Nkarta Inc Ordinary Shares NKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.30
- Day Range
- $2.24–2.34
- 52-Week Range
- $1.70–3.72
- Bid/Ask
- $2.04 / $2.45
- Shares Outstanding
- 71.62M
- Market Cap
- $166.89M
- Volume/Avg
- 302,399 / 662,130
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 106
- Website
- https://www.nkartatx.com
Valuation
|
Metric
|
NKTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.67 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NKTX
|
|---|---|
Quick Ratio | 7.76 |
Current Ratio | 7.98 |
Interest Coverage | — |
Quick Ratio
NKTX
Profitability
|
Metric
|
NKTX
|
|---|---|
Return on Assets (Normalized) | −25.41% |
Return on Equity (Normalized) | −32.80% |
Return on Invested Capital (Normalized) | −29.57% |
Return on Assets
NKTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Dq%!!RD | LOCK|%C$>F | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mS!l$P> | LOCK|pnW< | $83B | |||
| argenx SE ADR
ARGX
| LOCK|GZlCVJ | LOCK|%$l | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lP!j$LM< | LOCK|RdnV | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Cx^!Vc& | LOCK|?%S | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&np&$r | LOCK|>LkV | $31B | |||
| Moderna Inc
MRNA
| LOCK|qJ^zhpN | LOCK|D^ | $25B | |||
| Incyte Corp
INCY
| LOCK|WXm@wyS | LOCK|?# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@gNg!S@ | LOCK|NQ? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^Nc!c<v | LOCK|>&# | $16B |
United States